NLRP3 and breast cancer: In conclusion, we revealed that breast cancer-induced NLRP3 activation results in the expression of PD-L1 in myeloid cells and proposed NLRP3 inhibition as a promising therapeutic approach to overcome anti-PD-1 resistance